SANTA MONICA, Calif. , May 24, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, announced today that its Chief Executive Officer, Dr.

SANTA MONICA, Calif. , May 18, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, announced today that, due to the continuing public health concerns relating to the

SANTA MONICA, Calif. , May 11, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the three months ended March 31, 2021 , and provided a

SANTA MONICA, Calif. , May 03, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the first quarter ended March 31, 2021

Pharmacodynamic study will compare OPNT003, nasal nalmefene, with nasal naloxone in reversing the respiratory depression produced by the synthetic opioid, remifentanil Top-line data expected in the fourth quarter This trial starts at a time when deaths resulting from opioid overdose are at record

SANTA MONICA, Calif. , March 31, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, has been awarded the third and final tranche of $1.8 million from the total grant of

SANTA MONICA, Calif. , March 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today announced the appointment of Lorianne Masuoka , M.D., to its Board of Directors,

SANTA MONICA, Calif. , March 04, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines to treat addictions and drug overdose, today reported financial results for the fourth quarter and year ended December 31, 2020

SANTA MONICA, Calif. , Feb. 22, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT), a specialty pharmaceutical company developing medicines for addictions and drug overdose, today announced it will report its financial results for the fourth quarter and year ended

SANTA MONICA, Calif. , Feb. 08, 2021 (GLOBE NEWSWIRE) -- Opiant Pharmaceuticals , Inc. (“Opiant”) (NASDAQ: OPNT) today announced the dosing of the first patient in a confirmatory pharmacokinetic (“PK”) study for OPNT003, nasal nalmefene, for the treatment of opioid overdose.